[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperpigmentation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperpigmentation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,71,100,129,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100625988","evaluation-of-efficacy-and-tolerabilty-of-melab3-serum-in-combination-of-35-glycolic-acid-peeling-compared-to-35-glycolic-acid-peeling-alone-in-various-hyperpigmentation-conditions-100625988",false,"NCT07429786","Evaluation of Efficacy and Tolerabilty of MelaB3 Serum in Combination of 35% Glycolic Acid Peeling Compared to 35% Glycolic Acid Peeling Alone in Various Hyperpigmentation Conditions","Randomized Clinical Trial to Assess the Effectiveness and Tolerability of MELA B3 Serum in Combination With 35% Glycolic Acid Peel vs. 35% Glycolic Acid Peel for the Treatment of Various Hyperpigmentation Conditions (Melasma, Post-inflammatory Hyperpigmentation and Solar Lentigo) and Signs of Aging in a Population of Participants From the Autonomous City of Buenos Aires, Argentina.","Inclusion Criteria:\n\n1. Women and men\n2. From 30 to 70 years of age (inclusive)\n3. Good general health\n4. With any type of phototype\n5. Hyperpigmentation condition with average darkness \\> 3:\n\n   1. Epidermal or mixed melasma (determined by Wood's lamp examination at screening), mild to moderate melasma (IGA 1 or 2)\n   2. Post acne inflammatory hyperpigmentation (PIHP), mild to moderate (IGA 1 or 2) with no active acne and less than 10 inflammatory lesion on full face\n   3. Solar lentigo (SL) with a pigmentation score\\>5\n6. Willingness to protect oneself from the sun as much as possible for the duration of the study\n7. Willingness to avoid contraindicated products (irritants, other depigmenting agents)\n8. Signing of written informed consent\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding or with pregnancy plans.\n2. All contraindications for superficial peeling (for example, concomitant infectious processes or inflammatory processes that affect the skin barrier).\n3. Melasma with predominance of the pigmentary component at the dermis level, observed with Wood's light at the inclusion visit.\n4. Active acne with 10 or more inflammatory lesions.\n5. In the case of melasma, participants with recent change of contraception (less than 3 months) or less than 3 months since childbirth.\n6. Participant using irritating products (require a washout period of at least 2 weeks).\n7. Use of medications that may induce melasma, such as antiepileptics (requires a washout period of 1 month).\n8. Use of other products with depigmenting activity (requires a washout period of 1 month).\n9. Other facial dermatoses or known photosensitivity, or a pre-existing or latent dermatologic health condition and\u002For disease on the face (e.g., psoriasis, rosacea, acne, eczema, seborrheic dermatitis, severe excoriations) that, in the judgment of the investigator, are considered inappropriate for participation or may interfere with study results.\n10. Topical treatments applied to the face (requires a 2-week washout period).\n11. Scheduled facial procedures during the course of the study.\n12. Participants undergoing phototherapy (requires a 1-month washout period).\n13. Known hypersensitivity to study products.\n14. History of laser resurfacing procedures, intense pulsed light, facial radiofrequency, deep peeling, facial mesotherapy with tranexamic acid, botulinum toxin or dermal filler injections, or cosmetic procedures on the face within 6 months prior to the start of the study.\n15. Facial treatment with microdermabrasion within 6 weeks prior to study entry.\n16. Persons with visible tanning, scars, moles, excessive hair or other dermal conditions on the face that, in the judgment of the investigator, may influence the results of the study.\n17. History of skin cancer, immunosuppression or immunodeficiency disorders (including HIV infection or AIDS), or current use of immunosuppressive drugs.\n18. Uncontrolled disease such as asthma, diabetes, hypertension, hyperthyroidism or hypothyroidism. Persons with multiple health conditions may be excluded, even if controlled by diet or medication.\n19. Participation in another clinical trial within one week prior to entering this study.",true,"ALL","30 Years","70 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","Randomized clinical trial to assess the effectiveness and tolerability of Mela B3 serum in combination with 35% glycolic acid peel vs. 35% glycolic acid peel for the treatment of various hyperpigmentation conditions (melasma, post-inflammatory hyperpigmentation and solar lentigo) and signs of aging in a population of participants from the Autonomous City of Buenos Aires, Argentina.",[28,29,30,31],"Hyperpigmentation","Melasma","Solar Lentigo","Peeling","NOT_YET_RECRUITING","2026-02-17",{"date":35,"type":36},"2026-02-24","ACTUAL",{"date":38,"type":22},"2026-03-04",{"date":40,"type":22},"2026-06",{"name":42,"class":43},"Cosmetique Active International","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100617910","clinical-study-to-assess-safety-effectiveness-and-in-use-tolerability-of-saffron-extract-capsules-for-improving-skin-health-and-reducing-signs-of-aging-on-healthy-adult-male-and-female-subjects-100617910","NCT07324759","Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin Health and Reducing Signs of Aging on Healthy Adult Male and Female Subjects.","Effect of Saffron Extract Capsule Supplement on Skin Rejuvenation and Anti-Ageing in Healthy Adult Male and Female Subjects: Randomised, Double-Blind, Two-Group, Prospective, Multi-Centre Exploratory Study","GLOW","Inclusion Criteria:\n\n1. Age: 30 to 55 years (both inclusive) at the time of consent.\n2. Sex: Adult male and female having wrinkles and fine lines at crow feet's area, facial hyperpigmentation and dark spots such as tan, pimple marks, sunspots, age spots, uneven skin tone on both side of face.\n3. Females of childbearing potential should have a self-reported negative urine pregnancy test at the time of screening visit.\n4. Subjects should not have used any cosmetic, nutraceutical or therapeutic products for skin ageing in last 1 month.\n5. Subjects must be willing to stop using any cosmetics or any medical products for skin ageing for the duration of the study.\n6. Subjects are not allowed to participate in any other study until this study is complete.\n7. Subjects must be willing and able to follow the study directions and to return for all specified visits with the product.\n8. Subjects must agree to record each use of the test products in the subject's diary card on daily basis.\n9. Subjects must agree to record medication use during the study.\n\nExclusion Criteria:\n\n1. Subjects who are on steroids for last six months and using immunosuppressive, anti-inflammatory, or hormone-modulating medications that may interfere with study outcomes.\n2. Subjects who have used any cosmetic, nutraceutical or therapeutic products for skin last one months.\n3. Subjects currently using any oral supplement and topical products containing kojic acid, glycolic acid, niacinamide, alpha arbutin, vitamin C, retinoids, peptides, exfoliating acids, or any other skin-lightening, anti-ageing, or depigmenting agents within the past 4 weeks.\n4. Subjects with a known history of hypersensitivity, allergic reactions, or intolerance (such as drowsiness, stomach discomfort, nausea, or vomiting).\n5. Subjects with other dermatologic diseases whose presence or products could interfere with the assessment of study.\n6. Subjects that are pregnant and\u002For breastfeeding.\n7. The subject has a known allergy or sensitivity to product ingredients.\n8. Subjects if do not agree to limit sun exposure to affected areas such as face during prolonged sun exposure.\n9. The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject.\n10. The subject has any of the conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results.\n11. The subject is currently taking or has taken any medication, which the Investigator believes may influence the interpretation of the data.\n12. Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.","55 Years",{"count":54,"type":22},50,[25],"This is a randomized, double-blind, comparative, two-arm, prospective, interventional, multi-centre clinical study to evaluate the safety, efficacy, and in-use tolerability of test products, standardized saffron extract capsules, on skin rejuvenation and age-defying benefits in healthy adult male and female subjects.",[58,59,28,60],"Wrinkles","Fine Lines","Dark Spots","2025-12-24",{"date":63,"type":36},"2026-01-07",{"date":65,"type":22},"2026-01-01",{"date":67,"type":22},"2026-05-30",{"name":69,"class":70},"NovoBliss Research Pvt Ltd","OTHER",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100598160","the-effectiveness-of-a-novel-lip-product-containing-caulerpa-lentillifera-extract-for-reducing-lip-hyperpigmentation-100598160","NCT07067879","The Effectiveness of a Novel Lip Product Containing Caulerpa Lentillifera Extract for Reducing Lip Hyperpigmentation","Inclusion Criteria:\n\n* Understand the study protocol and provide informed consent after being informed of potential risks and benefits.\n* Refrain from using any other lip products, including lipstick, lip gloss, or lip conditioners, during the study period.\n\nExclusion Criteria:\n\n* Have a known allergy or sensitivity to cosmetic products or Caulerpa lentillifera.\n* Are on medication one month prior to study commencement.\n* Exhibit lip abnormalities such as malformation, inflammation, swelling, or sores.","18 Years","60 Years",{"count":80,"type":22},30,[25],"The goal of this clinical trial is to evaluate the efficacy of the novel lip product containing Caulerpa lentillifera extract on the appearance and perception of dark lips in Thai adults aged 18 to 60 who report concerns about darkened lips. The main question it aims to answer is: Can the novel lip product containing C. lentillifera extract will significantly improve the appearance and perception of dark lips in Thai adults by reducing hyperpigmentation compared to baseline measurements?\n\nParticipants will apply the lip product twice a day, in the morning after breakfast and before bedtime, and refrain from using other lip products throughout the clinical trial period (7 days).\n\nResearchers will compare the result to baseline measurements",[28],[85,86,87,88],"Lip hyperpigmentation","Seaweed","Antera3D","Lip care","RECRUITING","2025-07-07",{"date":92,"type":36},"2025-07-16",{"date":94,"type":22},"2025-07-23",{"date":96,"type":22},"2025-08-13",{"name":98,"class":70},"Chulalongkorn University",1,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":16,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":99},"100467144","efficacy-and-tolerability-of-a-hybrid-fractional-laser-for-the-treatment-of-acne-scars-in-patients-with-skin-of-color-100467144","NCT05362929","Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color","Inclusion Criteria:\n\n* Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for acne scarring\n* Subject must voluntarily sign and date an IRB approved informed consent form\n* Subjects with diagnosis of acne scarring recorded over the past 6 months\n* Able to read, understand and voluntarily provide written informed consent.\n* Subject is determined to be healthy, non-smoker\n* Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements.\n* Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period.\n\nExclusion Criteria:\n\n* Subjects does not have the capacity to consent to the study\n* subject underwent any acne scar treatments in the past 6 months prior to enrollment in the study\n* Subject has active papulopustular or cystic acne within the past 6 months.\n* Any history of keloidal scarring.\n* Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months.\n* History of immunosuppression\u002Fimmune deficiency disorders (including AIDS and HIV infection), and\u002For any history of systemic chemotherapy for prior 12 months.\n* History or current use of the following prescription medications:\n\nImmunosuppressive medications\u002Fbiologics, 6 months prior to and during the study\n\n* Accutane or other systemic retinoids within the past twelve months\n* Smoking or vaping in the past 12 months.\n* History of photosensitivity and\u002For connective tissue disease\n* History of hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders.\n* History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism.\n* History of ongoing pregnancy, active breastfeeding, cancer, and epilepsy",{"count":107,"type":22},46,[25],"The investigators aim to investigate the efficacy and tolerability of a hybrid non-ablative\u002Fablative laser for acne scarring in skin of color.",[111,28,112],"Acne Scars - Mixed Atrophic and Hypertrophic","Laser-Induced Hyperpigmentation",[114,115,116,117,118,119],"skin of color","fitzpatrick skin type III","fitzpatrick skin type IV","fitzpatrick skin type V","acne scarring","sciton","2025-05-20",{"date":122,"type":36},"2025-05-22",{"date":124,"type":36},"2023-10-11",{"date":126,"type":22},"2026-09",{"name":128,"class":70},"Albert Einstein College of Medicine",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":16,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":141,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":99},"100535564","efficacy-and-tolerability-of-tested-formula-after-3-months-of-treatment-of-facial-hyperpigmentation-of-3-origins-100535564","NCT06253468","Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins","Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins: Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo","Inclusion Criteria:\n\n* all phototypes\n* only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo\n* female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study\n* patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study\n\nExclusion Criteria:\n\n* female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study\n* male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline)\n* patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc.\n* severe melasma, dermal melasma\n* patient with facial pigmentary disorders other than those described in inclusion criteria\n* patient who has used topical depigmenting agents such as hydroquinone and derivatives, glycolic acid, kojic acid, retinoids and derivatives, azelaic acid, niacinamide within 1 month prior to Day 0\u002FBaseline visit\n* patient who has used systemic treatments such as tranexamic acid and oral melatonin within 1 month prior to Day 0\u002FBaseline visit;\n* patient who has used drugs inducing pigmentation such as tetracyclines, fluoroquinolones, antiepileptics within 1 month prior to Day 0\u002FBaseline visit",{"count":137,"type":22},72,[25],"The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.",[28],[142,143,144,145],"facial hyperpigmentation","melasma","acne induced PIHP","solar lentigo","2024-08-03",{"date":148,"type":36},"2024-08-06",{"date":150,"type":36},"2024-06-14",{"date":152,"type":22},"2025-03",{"name":42,"class":43},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":16,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":139,"conditions":162,"keywords":163,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":99},"100536720","efficacy-and-tolerability-of-the-tested-formula-after-3-months-in-treatment-of-facial-hyperpigmentation-of-3-origins-100536720","NCT06268496","Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins",{"count":160,"type":22},60,[25],[28],[142,143,144,145],"2024-07-10",{"date":166,"type":36},"2024-07-12",{"date":168,"type":36},"2024-03-14",{"date":170,"type":22},"2024-07",{"name":42,"class":43}]